TRIAL DETAIL

Masitinib 2nd Line versus Sunitinib in Advanced GIST

Drug:
Trial Name:
Masitinib 2nd Line versus Sunitinib in Advanced GIST
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Unknown
Phase:
3
Start Date 05/15/2012
Age of Trial (yrs) 9.6
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
AB110002
Sponsor:
AB Science
Patient Contact:
Axel Le Cesne, M.D., Ph.D. +33 1 42 11 43 16 lecesne@igr.fr
Contact email:
Contact Phone:
Randomized:
Randomized
IV or Oral:
Oral
Trial Notes:

AB Science Press Release 5/15/2011: This is a phase 3, multicenter, randomized, open-label, controlled, two-parallel group study evaluating the efficacy and safety of masitinib as compared with sunitinib (Sutent®) in GIST patients after progression under imatinib (Gleevec®). This study will recruit around 200 patients from 50 sites around the world, randomized with a 1:1 ratio between masitinib and sunitinib. The primary end-point is overall survival (OS).

Trial Links

Trial Results

Drug Information

AB Science website
 
Comparative Toxicogenomics Database
 
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
 
Masitinib Phase II Trial Reports Benefit in New GISTs
 
Masitinib, (AB1010), a potent and selective TKI of targeting KIT (PDF)
 
Press Release - Masitinib extends overall survival in randomized phase II trial for GIST vs. Sutent for second line treatment
 
Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study.
 
AB Science reports phase 3 study results of masitinib in combination with Gemzar® for treatment of pancreatic cancer. Read more: AB Science reports phase 3 study results of masitinib in combination with Gemzar® for treatment of pancreatic cancer. - FiercePharma http://www.fiercepharma.com/press-releases/ab-science-reports-phase-3-study-results-masitinib-combination-gemzar-treat#ixzz2AsvsdSb7 Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma
 
AB Science announces a voluntary hold in the clinical studies of Masitinib worldwide (Jun, 2021).
 

Trial Sites

Name
Address
City
State
Zip
Country
660 S. Euclid Ave
St. Louis
MO
63110
USA
203 Cox Boulevard
Goldsboro
NC
27534
USA
5841 S. Maryland Ave
Chicago
IL
60637
USA
1500 East Medical Center Dr
Ann Arbor
MI
48109
USA
229 Cours Argonne
Bordeaux
Gironde
33076
France
Jacksonville
FL
32224
USA
Rochester
MN
55905
USA
1475 Northwest 12th Ave
Miami
FL
33136
USA
Amsterdam
Netherlands
Brussels
Belgium
Wilrijkstraat 10
Antwerp
Belgium
Grieskirchner road 42
Vienna (Wien)
A-4600
Austria
5. med. Abteilung
Vienna (Wien)
Austria
Munich
D-81675
Germany
Breisacher Straße 117
Freiburg
D-79106
Germany
50937 Koln
GERMANY
Mannheim
68167
Germany